1
|
Osazuwa-Peters N, Osazuwa-Peters O, Adjei Boakye E, Abouelella D, Barnes J, Bates N, Ramos K. 1428P Suicidal outcomes among cancer survivors: Examining associations with depression and non-medical pain prescriptions. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
2
|
Thorpe C, Liokati I, Boyle E, Mohan H, Bates N, Martin S, Kennelly R, Hanly A, Winter D, Carrington EV. 935 Identification and Management of Electrolyte Abnormalities in Surgical Patients Requiring Total Parenteral Nutrition: An Audit of Current Practice at A University Hospital. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Aim
Electrolyte abnormalities are a common and serious consequence of nutritional deficiencies when patients are nil-by-mouth. Timely intervention with a multidisciplinary approach is known to improve outcome. This audit aimed to assess adequacy of initial electrolyte management and timing of dietetics referral in acute surgical patients requiring total parenteral nutrition in a university hospital.
Method
A retrospective audit of all general surgery patients referred to dietetics for total parenteral nutrition between January-December 2019 was performed. The following audit standards (from the time following admission) were applied: monitoring of electrolytes every 48-hours, treatment of electrolyte abnormalities within 24-hours of discovery; and referral to the dietetics service within 48-hours of nil-by-mouth being commenced.
Results
Data from 52 patients (27 females, median age 66) were analysed. Fifty-one (98%) had electrolytes measured every 48-hours, however magnesium, phosphate and/or calcium were not measured prior to dietetics input in 9 (17%). Forty electrolyte abnormalities requiring treatment were found in 28 patients (54%), though only 18 (64%) commenced treatment within 24-hours. The most common electrolyte abnormalities not corrected within 24-hours were phosphate and calcium (50%). 46% of patients were referred to dietetics after 48-hours of nil-by-mouth status.
Conclusions
In our unit, we found that basic electrolytes were frequently monitored in patients placed nil-by-mouth, however calcium, phosphate and magnesium were often omitted prior to dietetics input, and correction of abnormalities was sometimes delayed. Introduction of a local protocol-based approach for electrolyte monitoring with streamlined dietetics referrals is likely to improve adherence to best practice.
Collapse
Affiliation(s)
- C Thorpe
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
- University College Dublin, Dublin, Ireland
| | - I Liokati
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - E Boyle
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - H Mohan
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - N Bates
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - S Martin
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - R Kennelly
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - A Hanly
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - D Winter
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
| | - E V Carrington
- Department of Colorectal Surgery, St. Vincent's University Hospital, Dublin, Ireland
- Department of Surgery and Cancer, Imperial College, London, United Kingdom
| |
Collapse
|
3
|
Ho B, Ellison J, Edwards N, Bates N. Prevalence of vitamin D analogue toxicity in dogs. Clin Exp Dermatol 2020; 46:577-578. [PMID: 33151582 DOI: 10.1111/ced.14499] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Accepted: 11/02/2020] [Indexed: 11/29/2022]
Affiliation(s)
- B Ho
- Dermatology Department, St George's Hospital, London, UK
| | - J Ellison
- Veterinary Poisons Information Service, London, UK
| | - N Edwards
- Veterinary Poisons Information Service, London, UK
| | - N Bates
- Veterinary Poisons Information Service, London, UK
| |
Collapse
|
4
|
Ho B, Bates N, Edwards N, Robinson N, Ellison J. Under‐recognised effects on our canine and feline companions with 5‐fluorouracil use. Br J Dermatol 2020; 182:819. [DOI: 10.1111/bjd.18693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- B. Ho
- Dermatology Department St George's University Hospitals NHS Foundation Trust London U.K
| | - N. Bates
- Veterinary Poisons Information Service London U.K
| | - N. Edwards
- Veterinary Poisons Information Service London U.K
| | - N. Robinson
- Veterinary Poisons Information Service London U.K
| | - J. Ellison
- Veterinary Poisons Information Service London U.K
| |
Collapse
|
5
|
Bates N, Hargraves C, Killen C, King L. An evaluation of vitamin and mineral status of home parenteral nutrition patients at a home parenteral centre. Clin Nutr ESPEN 2018. [DOI: 10.1016/j.clnesp.2018.09.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Coote K, Kishore K, Bates N, Prasad P. P13.12 Hiv sensitisation health care worker training in vanuatu. Br J Vener Dis 2015. [DOI: 10.1136/sextrans-2015-052270.510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
7
|
Bates N, Edwards N. Benzalkonium chloride exposure in cats: a retrospective analysis of 245 cases reported to the Veterinary Poisons Information Service (VPIS). Vet Rec 2015; 176:229. [DOI: 10.1136/vr.102653] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- N. Bates
- Veterinary Poisons Information Service (VPIS); Medical Toxicology and Information Services; Mary Sheridan House, 13 St Thomas Street London SE1 9RY UK
| | - N. Edwards
- Veterinary Poisons Information Service (VPIS); Medical Toxicology and Information Services; Mary Sheridan House, 13 St Thomas Street London SE1 9RY UK
| |
Collapse
|
8
|
Bates N, Rawson-Harris P, Edwards N. Common questions in veterinary toxicology. J Small Anim Pract 2015; 56:298-306. [DOI: 10.1111/jsap.12343] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Revised: 12/05/2014] [Accepted: 01/05/2015] [Indexed: 11/29/2022]
Affiliation(s)
- N. Bates
- Veterinary Poisons Information Service (VPIS); Medical Toxicology and Information Services; London SE1 9RY
| | - P. Rawson-Harris
- Veterinary Poisons Information Service (VPIS); Medical Toxicology and Information Services; London SE1 9RY
| | - N. Edwards
- Veterinary Poisons Information Service (VPIS); Medical Toxicology and Information Services; London SE1 9RY
| |
Collapse
|
9
|
Bates N, Chatterton J, Robbins C, Wells K, Hughes J, Stone M, Campbell A. Lipid infusion in the management of poisoning: a report of 6 canine cases. Vet rec case rep 2013. [DOI: 10.1136/vetreccr.101036rep] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- N. Bates
- Veterinary Poisons Information ServiceMedical Toxicology and Information ServicesMary Sheridan HouseLondonSE1 9RYUK
| | - J. Chatterton
- Grove Veterinary Centre2 Hibbert Street, New MillsHigh PeakDerbyshireSK22 3JJUK
| | - C. Robbins
- Castle Vets Pet Healthcare Centre1 Tilehurst RoadReadingRG1 7TWUK
| | - K. Wells
- Kingfisher Veterinary PracticeSouth Road Vet CentreMountfield RoadTauntonSomersetTA1 3BQUK
| | - J. Hughes
- Blake Veterinary GroupShowground RoadBridgwaterSomersetTA6 6AJUK
| | - M. Stone
- RSPCA Bristol & District Branch48 Albert RoadSt PhilipsBristolBS2 0XAUK
| | - A. Campbell
- Veterinary Poisons Information ServiceMedical Toxicology and Information ServicesMary Sheridan HouseLondonSE1 9RYUK
| |
Collapse
|
10
|
Bates N, Chatterton J, Robbins C, Wells K, Hughes J, Stone M, Campbell A. Lipid infusion in the management of poisoning: a report of 6 canine cases. Vet Rec 2013; 172:339. [PMID: 23423482 DOI: 10.1136/vr.101036] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Intravenous administration of lipid is a relatively new treatment in the management of toxicity from lipophilic compounds. It is used in human medicine in the treatment of toxicity from lipophilic local anaesthetics and cardiotoxic drugs and can result in dramatic improvement in clinical status. We present six cases of poisoning in dogs successfully treated with lipid infusion after ingestion of ivermectin (3), moxidectin (2) and baclofen (1). The dogs ranged in age from eight weeks to 14 years, and weighed 4-30 kg. Intravenous lipid therapy was started between six and eight hours and 22 hours after ingestion, and all the dogs responded well. In four dogs, there was clinical improvement within one hour; one had improved within two hours and the other within 4.5 hours of lipid administration. The only adverse effect of lipid infusion reported was mild swelling and pain after extravasation in one case which resolved with conservative management. All the dogs were discharged within 24-52 hours after exposure (7-46 hours after the start of lipid administration), and none developed any apparent sequelae.
Collapse
Affiliation(s)
- N Bates
- Veterinary Poisons Information Service, Medical Toxicology and Information Services, Mary Sheridan House, London SE1 9RY, UK.
| | | | | | | | | | | | | |
Collapse
|
11
|
Salazar LG, Slota M, Higgens D, Coveler A, Dang Y, Childs J, Bates N, Guthrie K, Waisman J, Disis ML. Abstract P5-16-04: A phase I study of a DNA plasmid based vaccine encoding the HER-2/neu intracellular domain in subjects with HER2+ breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
HER2+ breast cancer (BC) is associated with early disease relapse, usually to distant sites. This would suggest relapse is due to residual microscopic disease. Generation of vaccine-induced HER2-specific CD4+ T helper immunity (Th1) may result in immunologic eradication of residual HER2+ tumor cells and subsequent development of immunologic memory and epitope spreading (ES), which has been associated with a survival benefit in vaccinated BC patients. We have shown HER2 peptide-based vaccines can generate immunity in BC however, more recently we developed a plasmid DNA based vaccine (pNGVL3-hICD) which may have additional advantages over synthetic peptides. DNA vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and Th1 immunity. Plasmid DNA can also remain at the vaccine site, providing a constant source of antigen. Intradermal (i.d.) delivery of DNA vaccines with GM-CSF as adjuvant may enhance immunogenicity due to local influx of dermal Langerhans cells. We have recently completed a phase I trial utilizing pNGVL3-hICD in optimally treated stage III and IV HER2+ BC patients and have defined vaccine safety profile, optimal dose and schedule; and demonstrated vaccine biologic activity.
Methods: A total of 66 subjects with stage III and IV HER2+ BC in complete remission were enrolled sequentially into 1 of 3 pNGVL3-hICD dose arms (22 subjects/arm): Arm 1=10µg, Arm 2=100 µg, and Arm 3 = 500µg. All vaccines were admixed with 100µg GM-CSF and given i.d. monthly for a total of 3 vaccines. Toxicity was assessed at baseline, during vaccination and at follow-up. Immune responses to HER ICD and ECD were assessed with IFN-γ ELISPOT at baseline and serially through week 60 post-vaccination. Linear regression analysis was used to compare differences in immune responses from baseline over the whole study period between dose arms. Vaccine site skin biopsies and peripheral lymphocytes were serially analyzed for plasmid persistence via RT-PCR.
Results: 64 subjects (20 in Arm 1; 22 in Arm 2; 22 in Arm 3) completed 3 vaccines. Age, stage/status, number of previous chemotherapy regimens, and use of bisphosphonate and trastuzumab therapies was similar across dose arms. Vaccine-related toxicity was primarily Grade 1/2 injection site reactions, myalgias, arthralgias and not significantly different between arms; no cardiac or grade IV toxicity was observed. Immune responses to HER2 ICD were significantly better in Arms 2 and 3 vs Arm 1 (p = 0.001 and 0.002, respectively) but not statistically different between Arms 2 and 3. 38 patients had DNA plasmid persistence at the vaccination site with no difference between arms. There has been no detection of DNA plasmid in lymphocytes from patients in all arms. Analyses of survival and ES (HER ECD immune responses) are on-going and will be presented.
Conclusions: pNGVL3-hICD was safe and effectively induced persistent HER2 ICD specific Th1 immunity without increased cardiac toxicity. Moreover, immunity was present more than 1 year after end of vaccination, indicative of vaccine-induced immunologic memory.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-16-04.
Collapse
Affiliation(s)
- LG Salazar
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - M Slota
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - D Higgens
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - A Coveler
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - Y Dang
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - J Childs
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - N Bates
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - K Guthrie
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - J Waisman
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| | - ML Disis
- University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA
| |
Collapse
|
12
|
Sutton NM, Bates N, Campbell A. Canine adder bites in the UK: a retrospective study of cases reported to the Veterinary Poisons Information Service. Vet Rec 2011; 169:607. [PMID: 21868437 DOI: 10.1136/vr.d4695] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
This retrospective study examined cases with follow-up reported to the Veterinary Poisons Information Service (VPIS) between September 1985 and December 2010. Most bites (69.2 per cent) occurred between April and July, particularly between 15:00 and 16:00 hours. Adder bites were more frequently reported in the south-east of England, particularly in Surrey. Swelling to the face and limbs was common, as was lethargy, depression, hyperthermia and tachycardia. About two-thirds of dogs developed both systemic and local effects, while a third developed local effects alone. Initial clinical effects usually occurred within two hours, with full recovery typically occurring five days after the bite. Antivenom was used in 55.9 per cent of cases and appeared to significantly reduce duration of oedema from an average of 94 to 47 hours. Adder bites can cause significant morbidity (97 per cent of dogs were symptomatic), but mortality is low (4.6 per cent died).
Collapse
Affiliation(s)
- N M Sutton
- Veterinary Poisons Information Service, Medical Toxicology Information Services, Guy's & St Thomas' NHS Foundation Trust, Mary Sheridan House, Guy's Hospital, Great Maze Pond, SE1 9RT, UK.
| | | | | |
Collapse
|
13
|
Salazar L, Higgins D, Childs J, Bates N, Dang Y, Slota M, Coveler A, Waisman J, Disis M. Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: CD4+CD25+Foxp3+ regulatory T cells (Tregs) are potent suppressors of CD4+ and CD8+ T cells, produce the immunosuppressive cytokine TGF-β; and as such, may down-regulate immune responses to tumor antigens. Additionally, Tregs are increased in the peripheral blood (PB) and tumors of breast cancer patients; and are associated with poor prognosis. Depletion of PB and tumor-associated Tregs may induce anti-tumor immunity by augmenting anti-tumor effector T cells and enhancing endogenous tumor specific immunity. ONTAK®, a diphtheria/IL-2R fusion protein depletes PB Tregs when given intravenously (IV) and selectively targets tumor cells that overexpress IL-2R. Breast tumors have been shown to overexpress IL-2R which is associated with their malignant potential. We hypothesized that ONTAK® could (1) have direct anti-tumor activity in breast cancers that overexpress IL-2R, and (2) deplete Tregs resulting in generation of functional immune effector cells and enhanced anti-tumor immunity. A phase I-II study was conducted to evaluate the safety of IV ONTAK® and assess its effect on Tregs and endogenous immunity in patients with advanced refractory breast cancer.Materials and Methods: 15 patients with progressive stage IV breast cancer following standard therapy were sequentially enrolled and received IV ONTAK® 18 mcg/kg/day on Days1-5 every 21 days for a total of 6 cycles and/or maximal tumor response. Toxicity was evaluated on Days 1 8, and 14 of each cycle per CTEP CTCAE v3.0. Tumor response was evaluated per RECIST at baseline, and after cycles 3 and 6. PB was collected at baseline and after cycles 2, 4, and 6 for evaluation of Tregs, sIL-2R, and endogenous tumor-antigen specific T cell immunity to HER-2/neu (HER2), CEA, and MAGE-3 via RT-PCR, LUMINEX and IFN-γ ELISPOT assay, respectively. Expression of IL-2R in patient paraffin embedded tumor samples was analyzed by IHC analysis.Results: 15 subjects have been enrolled and 14/15 have completed treatment; median age is 58 years (range, 32-69) and median salvage regimens is 3 (range, 2-8). 7/14 subjects had triple negative tumors. 7 subjects completed 1-2 and 7 completed 3-6 ONTAK® cycles, respectively. 4 subjects who completed 6 cycles of ONTAK® had SD or PR per RECIST. ONTAK®-related toxicities have been primarily grade I and II fatigue, nausea, and headache; and transient grade 3 hypoalbuminemia and lymphopenia. Preliminary data in 2 subjects shows enhanced tumor-antigen specific T cell immunity defined as mean tumor antigen-specific T cell precursors:PBMC to CEA (pre- ONTAK® 1:250,000; post- ONTAK® 1:15,000) and HER2 (pre- ONTAK® 1:63,000; post- ONTAK® 1:6,312). Immunologic analyses are ongoing and will be presented along with clinical data on all patients.Conclusions: ONTAK® is well-tolerated when used as a salvage regimen in heavily pretreated breast cancer patients. Additionally, ONTAK® treatment can enhance endogenous immunity to known breast cancer antigens and potentially lead to more effective eradication of tumor.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4130.
Collapse
Affiliation(s)
| | | | | | | | - Y. Dang
- 1University of Washington, WA,
| | | | | | | | | |
Collapse
|
14
|
Disis M, Dang Y, Bates N, Higgins D, Childs J, Slota M, Coveler A, Jackson E, Waisman J, Salazar L. Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Vaccine Given Concurrently with Trastuzumab in Patients with Newly Diagnosed Advanced Stage Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
HER2 is a tumor antigen in breast cancer and several trials have demonstrated that breast cancer patients can be immunized against this protein. We have developed HER2 peptide based vaccines that are aimed at eliciting CD4+ Th1 tumor antigen specific T cell responses. Th1 effectors provide immunologic memory, enhance cross priming which will allow the elaboration of tumor specific CD8+ T cells, and stimulate epitope spreading which we have shown to be a potential biomarker of clinical response. 52 patients will be enrolled with the primary objective to determine relapse free survival after active immunization. Eligible patients are newly diagnosed with Stage III (B or C) or Stage IV breast cancer and begin vaccination within 6 months of starting maintenance trastuzumab. This interim report will present data on the first 25 patients enrolled; 21 stage IV and 4 locally advanced patients. The vaccine is well tolerated with all adverse events (AE) being Grade I or 2. The most common AE is injection site reaction. Moreover, the combination of HER2 vaccination with trastuzumab did not result in additive cardiac toxicity in these patients. Immune responses were evaluated by IFN-gamma ELISPOT. To date, 88% of patients immunized developed significant immunity to the components of the ICD vaccine. The majority, 75%, developed robust immunity to the HER2 protein. Our group has recently demonstrated that a broadening of immunity throughout the HER2 protein, to components of the protein that weren't in the vaccine, i.e. epitope spreading, may be associated with improved survival in vaccinated patients. 63% of immunized patients demonstrated evidence of intramolecular epitope spreading. We questioned whether such high frequencies of homing Type 1 T cells might modulate the immunosuppressive tumor microenvironment, so we evaluated whether circulating serum immunosuppressive cytokines were impacted by immunization. TGF-beta is an immunosuppressive cytokine secreted by tumor stroma and regulatory T cells. We found that the levels of serum TGF-beta decreased significantly in the majority of patients after vaccination. We further analyzed the correlation between the change of serum levels of TGF-beta post vaccination and HER2 ICD vaccine-induced T cell responses. We found that the greater the magnitude of the HER2 specific T cell response, as demonstrated by IFN-gamma secretion, the greater the decrease in serum TGF-beta (p=0.0045, r=0.742). The correlation between the increased epitope spreading T cell response and decreased levels of TGF-beta was even more significant (p=0.0003). The median overall survival has not been reached with 100% of patients alive at this time. Relapse free survival data will be presented.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5102.
Collapse
Affiliation(s)
| | - Y. Dang
- 1University of Washington, WA,
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Bates N, Higgins D, Childs J, Boettcher M, Salazar L, Disis M. The Impact of National Press Coverage on Early Phase Clinical Trial Recruitment and Enrollment. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The American Society of Clinical Oncologists reports that only 5% of cancer patients ultimately enroll in a clinical trial. According to the National Cancer Institute, one key barrier to participation is a lack of knowledge about clinical trials, both on behalf of oncologists and the patients themselves. Unfortunately, many investigator-initiated and academic clinical trials simply do not have budgets that permit implementation of large-scale recruitment efforts. Recent experience by our group demonstrates that press coverage by national media is a particularly effective tool for generating public interest in clinical research, as well as increasing trial enrollment.In the third quarter of 2008, our academic translational research group was featured on a national news program. In the week following the broadcast, our group's website, which had been listed in the broadcast and accompanying web story, received an unprecedented number of hits. Not only did the broadcast generate interest in our group's research; more specifically, it translated to substantial increases in potential clinical trial candidates, and subsequently, increased trial enrollment. In the month following the broadcast, our group received 125 new clinical trial inquiries as a result of the feature. That number represented a seven-fold increase in new inquiries during the same period in 2007. Of those 125 contacts, more than half of patients were potentially eligible for one of our clinical trials based on an initial screening. From November 2008 to the present, nearly one-third of all clinical trial enrollments can be attributed to the news story. Enrollment to the vaccine trial specifically described in the news feature increased four fold in comparison to the same 6-month period in 2008-2009, with half of all new enrollments attributable to the news feature.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6078.
Collapse
|
16
|
Sutton NM, Bates N, Campbell A. Factors influencing outcome of Vitis vinifera (grapes, raisins, currants and sultanas) intoxication in dogs. Vet Rec 2009; 164:430-1. [PMID: 19346542 DOI: 10.1136/vr.164.14.430] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- N M Sutton
- Veterinary Poisons Information Service (London), Medical Toxicology Unit, Avonley Road, New Cross, London SE14 5ER.
| | | | | |
Collapse
|
17
|
Affiliation(s)
- N M Sutton
- Medical Toxicology Unit, Veterinary Poisons Information Service (London), Avonley Road, New Cross, London SE14 5ER.
| | | | | |
Collapse
|
18
|
Salazar LG, Wallace D, Mukherjee P, Higgins D, Childs J, Bates N, Coveler AL, Disis ML. HER2/neu (HER2) specific T-cell immunity in patients with HER2+ inflammatory breast cancer (IBC) and prognosis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3057 Background: IBC is rare, highly aggressive, and associated with worse prognosis when compared to non-IBC tumors. Moreover, multimodality treatment has had little impact on overall prognosis. HER2 is overexpressed in about 40% of IBC tumors and is associated with worse overall survival (OS). We have developed vaccines that elicit both HER2-specific CD4+ and CD8+ T-cell immunity in HER2+ cancer patients. Generation of HER2-specific T-cell immunity could (1) target immunogenic and biologically relevant proteins such as HER2 in IBC, (2) result in immunogenic eradication of HER2+ tumor cells, and (3) potentially prevent disease relapse when used in the adjuvant setting after standard therapy. A retrospective analysis of IBC patients immunized with HER2 vaccines was conducted to better understand the development of HER2-specific T-cell immunity and its possible impact on overall prognosis in IBC. Methods: Clinical and immunological data of IBC patients enrolled in University of Washington IRB approved HER2 vaccine trials was collected and reviewed. 27 patients immunized between 1996–2008 were identified; and 24/27 subjects who received vaccines designed to elicit both CD4+/CD8+ immunity were included in immunologic and survival analysis. The 24 subjects received either a HER2 DNA or HER2 peptide-based vaccine that were admixed with GM-CSF and given intradermally monthly for a total of 3 DNA or 6 peptide vaccines. Immune responses were assessed via IFN-γ ELISPOT at baseline and post-vaccination. Results: All 24 subjects had stage III IBC and median age was 48 (range 34–77). 10/24 (42%) patients had ER/PR+ tumors, 9/24 (37%) had received trastuzumab, and 15/24 (62%) had received multimodality treatment (chemotherapy, mastectomy, radiotherapy). 12/18 subjects (66%) evaluable for immunologic response developed HER2-specific T-cell immunity post-vaccination. Median OS for patients (n=6) not generating HER2-specific immunity was 31 months and median OS for the 12 patients who developed HER2-specific immunity has not been reached at median follow-up of 46 months, (p=0.026). Conclusions: Patients with IBC are able to generate HER2-specific T-cell immunity after HER2 vaccination, and development of HER2-specific immunity may impact survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | | | - J. Childs
- University of Washington, Seattle, WA
| | - N. Bates
- University of Washington, Seattle, WA
| | | | | |
Collapse
|
19
|
Salazar LG, Slota M, Wallace D, Higgins D, Coveler AL, Dang Y, Childs J, Bates N, Waisman J, Disis ML. A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3054 Background: HER2 is overexpressed in 25% of breast cancers and plays a role in the malignant transformation of cells. Vaccine-induced immunity against the HER2 ICD correlates with antitumor responses in animal models. DNA-based vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and T helper immune responses. Plasmid DNA can also remain at the vaccine site, providing a constant source of antigen. However, DNA vaccines have been poorly immunogenic due in part to inefficient APC transfection. Intradermal (i.d.) delivery of DNA vaccines with GM-CSF as adjuvant may enhance immunogenicity due to local influx of dermal Langerhans cells. A phase I study was conducted to evaluate the safety and immunogenicity of a DNA-based vaccine encoding the HER2 ICD. Methods: 44 subjects with stage III and IV HER2+ breast cancer in complete remission were enrolled sequentially into 2 vaccine arms (22 subjects/arm) and received 10μg pNGVL3-hICD (Arm 1) or 100μg pNGVL3-hICD (Arm 2). All vaccines were admixed with 100μg GM-CSF and given i.d. monthly for a total of 3 vaccines. Toxicity was assessed at baseline, during vaccination, and at follow-up. Immune responses were assessed with IFN-γ ELISPOT at baseline and post-vaccination. Vaccine site biopsies were analyzed for plasmid persistence via RT-PCR, 1 and 6 months after vaccination. Results: 43 subjects (21 in Arm 1; 22 in Arm 2) completed 3 vaccines. Vaccine-related toxicity in both arms was primarily grade I/II; no cardiac or grade IV toxicity was observed. 13/21 (62%) subjects in Arm 1 developed T-cell immunity, defined as HER2-specific T cell precursors:PBMC, to the HER2 protein (median 1:5,972, range 1:717–1:3,000,000) and to p776, a HER2 pan DR binding epitope (median 1:3,150, range 1:543–1:108,696). 13/19 (68%) subjects in Arm 1 had persistent plasmid DNA at the vaccine site. ELISPOT and RT-PCR analysis for Arm 2 are on-going. Conclusions: Immunization with a DNA plasmid-based HER2 vaccine is safe and immunogenic. Moreover, plasmid DNA persists at the vaccine site post-immunization and HER2+ cancer patients are able to develop immunity to the HER2 ICD. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. G. Salazar
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - M. Slota
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - D. Wallace
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - D. Higgins
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - A. L. Coveler
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - Y. Dang
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - J. Childs
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - N. Bates
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - J. Waisman
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| | - M. L. Disis
- University of Washington, Seattle, WA; Breastlink Medical Group, Inc., Long Beach, WA
| |
Collapse
|
20
|
Disis ML, Salazar LG, Coveler A, Waisman J, Higgins D, Childs J, Bates N, Dang Y. Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3000] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3000 Background: Adoptive T-cell therapy has shown promise in the treatment of advanced-stage melanoma. We have previously reported that expansion of HER2-specific T cells from peripheral blood mononuclear cells (PBMC) can be greatly facilitated by vaccine-priming. In this study, we evaluated the safety and clinical efficacy of infusion of HER2-specific T cells in patients with advanced HER2 overexpressing cancers. Methods: 10 patients with progressive HER2+ metastatic breast and ovarian cancer, not considered curable by conventional therapies, will be enrolled in this study. The patients must have been pre-immunized with a HER2-specific vaccine. Three escalating doses of T cells are given at 10-day intervals. Cyclophosphamide or denileukin diftitox is administrated before the first dose of T cells. Results: To date, 5 of 10 subjects have been enrolled. T cells were expanded with HER2-specific class II restricted peptides. After in vitro expansion cell products were >95% CD3+ with an average of 35% CD4+ and 60% CD8+ T cells. The maximal doses infused were 1x109-41x109 cells (median 10x109). Subjects tolerated the infusions well with the primary toxicity being related to the conditioning agent. Objective tumor regression has been observed in 2 of the 5 treated patients. One other patient has had stable disease after treatment. In patients with tumor regression, the magnitude of HER2-specific T cells in the infused product was 8-fold higher than that in patients without clinical responses. The total number of HER2-specific T cells infused was 43-fold higher in responding patients than in nonresponding patients. Moreover, HER2-specific CD4+ and CD8+ T cells persisted over a year and even augmented in magnitude post-infusion in responding patients. Conclusions: Adoptive transfer of autologous HER2 specific polyclonal T cells generated from PBMC after vaccine-priming is well tolerated and has shown evidence of some clinical efficacy in patients with advanced-stage HER2+ cancers. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. L. Disis
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - L. G. Salazar
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - A. Coveler
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - J. Waisman
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - D. Higgins
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - J. Childs
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - N. Bates
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| | - Y. Dang
- University of Washington, Seattle, WA; Breastlink, Los Angeles, CA
| |
Collapse
|
21
|
Wallace D, Disis M, Coveler A, Higgins D, Childs J, Bates N, Salazar L, Slota M, Dang Y, Waisman J. Association of the level of HER2/neu (HER2) gene amplification in breast cancer and the magnitude of antigen specific T-cell immunity achieved after HER2 vaccination. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3059 Background: Studies have demonstrated that the level of HER2 gene amplification in breast cancer, assessed by fluorescence in situ hybridization (FISH), correlates with favorable clinical response after treatment with trastuzumab. We questioned whether HER2 gene amplification impacted the development of HER2-specific T-cell immunity following immunization with a HER2 vaccine. Methods: Patients with HER2+ stage III or IV breast cancer, treated to complete remission or stable bone only disease, were enrolled in one of two concurrent clinical trials of HER2-specific vaccines. Eligibility criteria between the two studies were similar. Patients received either a plasmid DNA-based vaccine encoding the HER2 intracellular domain or a peptide-based vaccine composed of 3 HER2 class II epitopes. Peripheral blood was assessed for HER2-specific T-cell responses by interferon gamma (IFN-g) ELISPOT prior to, immediately after, and 6 months to 1 year after the end of vaccinations. Both immune response and FISH data were available on 31 patients. Results: Correlation of FISH levels to IFN-g spots/well in evaluable patients revealed the level of HER2 gene amplification was not related to the presence of pre-existent HER2-specific T-cell immunity prior to vaccination (p=0.43), the generation of a HER2-specific immune response after vaccination (p=0.35), or the persistence of the HER2-specific T-cell response (p=0.33). However, the magnitude of the T-cell response achieved was less as HER2 gene amplification increased (p=0.05). Conclusions: The level of HER2 gene amplification in the primary tumor can adversely impact the magnitude of HER2-specific T-cell immunity achieved after vaccination. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Wallace
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - M. Disis
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - A. Coveler
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - D. Higgins
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - J. Childs
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - N. Bates
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - L. Salazar
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - M. Slota
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - Y. Dang
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| | - J. Waisman
- University of Washington, Seattle, WA; Breastlink, Long Beach, CA
| |
Collapse
|
22
|
Bissett IP, Shannon DE, Bates N. CR10�MRI CRITERIA FOR SELECTING PATIENTS FOR PREOPERATIVE RADIOTHERAPY IN RECTAL CANCER. ANZ J Surg 2009. [DOI: 10.1111/j.1445-2197.2009.04915_10.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Bates N, Cullen G, Northall F, Edwards N. Potter's potions: aconite poisoning. Arch Emerg Med 2009; 26:309-10. [DOI: 10.1136/emj.2008.064584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Wiseman HM, Edwards JN, Bates N, Campbell A, Cullen G, Dauncey E, Dines AM, Farrow C, Fitzpatrick R, Jones A, Kennedy K, Hawkins L, McParland M, Monaghan J, Northall FS, Sturgeon K, Sutton N, Shaw D, Tizzard Z. Surveillance of poisons centre enquiries. Arch Emerg Med 2009; 26:309. [DOI: 10.1136/emj.2008.064568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
25
|
Valentijn AJ, Upton JP, Bates N, Gilmore AP. Bax targeting to mitochondria occurs via both tail anchor-dependent and -independent mechanisms. Cell Death Differ 2008; 15:1243-54. [PMID: 18437166 DOI: 10.1038/cdd.2008.39] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Bax is a member of the Bcl-2 family that, together with Bak, is required for permeabilisation of the outer mitochondrial membrane (OMM). Bax differs from Bak in that it is predominantly cytosolic in healthy cells and only associates with the OMM after an apoptotic signal. How Bax is targeted to the OMM is still a matter of debate, with both a C-terminal tail anchor and an N-terminal pre-sequence being implicated. We now show definitively that Bax does not contain an N-terminal import sequence, but does have a C-terminal anchor. The isolated N terminus of Bax cannot target a heterologous protein to the OMM, whereas the C terminus can. Furthermore, if the C terminus is blocked, Bax fails to target to mitochondria upon receipt of an apoptotic stimulus. Zebra fish Bax, which shows a high degree of amino-acid homology with mammalian Bax within the C terminus, but not in the N terminus, can rescue the defective cell-death phenotype of Bax/Bak-deficient cells. Interestingly, we find that Bax mutants, which themselves cannot target mitochondria or induce apoptosis, are recruited to clusters of activated wild-type Bax on the OMM of apoptotic cells. This appears to be an amplification of Bax activation during cell death that is independent of the normal tail anchor-mediated targeting.
Collapse
Affiliation(s)
- A J Valentijn
- Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, Manchester, UK
| | | | | | | |
Collapse
|
26
|
Abstract
The anatomy of the anal canal is complex but well demonstrated by MRI. Understanding the anatomy is a prerequisite for determining the true site and the extent of pathology, especially for surgical workup. In this article, the MRI anatomy of the anal canal has been displayed using highlighted MRI images and line diagrams.
Collapse
Affiliation(s)
- P Kashyap
- Department of Radiology, Auckland Public Hospital, Auckland, New Zealand.
| | | |
Collapse
|
27
|
Affiliation(s)
- N Bates
- Medical Toxicology Unit, London
| | | |
Collapse
|
28
|
Affiliation(s)
- N Bates
- National Poisons Information Service, London
| |
Collapse
|
29
|
Abstract
A 6-year-old boy developed respiratory distress, metabolic acidosis, severe esophageal and gastric burns, and a coagulopathy after ingestion of an unknown volume of methyl ethyl ketone peroxide (MEKP) in dimethyl phthalate. He was discharged from the pediatric intensive care unit 19 days postingestion but subsequently developed a stricture of the gastroesophageal junction and complete fibrosis of the middle third of the stomach, necessitating gastric resection and reconstruction. He was discharged 93 days postingestion on a program of dilation for the residual esophageal stricture. MEKP acts by initiating lipid peroxidation via free radical production that results in cellular dysfunction and death. Acetylcysteine, a glutathione precursor and possible free radical scavenger, may be of use in severe MEKP poisoning. This case demonstrates the severe effects that some industrial chemicals can have both systemically and locally at the point of contact with the gastrointestinal tract, as well as the long-term management required to ensure good quality of life.
Collapse
Affiliation(s)
- N Bates
- National Poisons Information Service, Medical Toxicology Unit, London SE14 5ER United Kingdom
| | | | | |
Collapse
|
30
|
|
31
|
Bates N. Acute poisoning: bleaches, disinfectants and detergents. Emerg Nurse 2001; 8:14-9. [PMID: 11935819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- N Bates
- National Poisons Information Service, London
| |
Collapse
|
32
|
Affiliation(s)
- N Bates
- National Poisons Information Service, London
| |
Collapse
|
33
|
Affiliation(s)
- N Bates
- National Poisons Information Service, London
| |
Collapse
|
34
|
Affiliation(s)
- S McCrea
- National Poisons Information Service, London
| | | |
Collapse
|
35
|
Affiliation(s)
- N Bates
- National Poisons Information Service, London
| | | |
Collapse
|
36
|
McCrea S, Bates N. Acute poisoning: antituberculosis drugs--clinical features and management. Emerg Nurse 1999; 7:17-20. [PMID: 10514621 DOI: 10.7748/en1999.04.7.1.17.c1268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S McCrea
- National Poisons Information Service, London
| | | |
Collapse
|
37
|
Bates N, Dines A. Acute poisoning: initial management and sources of information. Emerg Nurse 1997; 5:20-24. [PMID: 27238046 DOI: 10.7748/en.5.3.20.s22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Poisoning is responsible for 2-3 per cent of attendances to urban A&F. departments in the UK each year ( MacNamara et al 1996 ). It accounts for about 7 per cent of accidents in children under five years of age ( Consumer Safety Unit 1995 ). The National Poison Information Service (NPIS) deals with hundreds of emergency telephone enquiries every day. and the number of such calls has risen sharply in recent years. Figure 1 demonstrates the annual call load of NPIS (London). A&E nurses account for 42 per cent of these telephone enquiries.
Collapse
Affiliation(s)
| | - A Dines
- National Poisons Information Service (London)
| |
Collapse
|